Mandate

Vinge advises Industrifonden in connection with its investment in Anyfi Network

September 12, 2012

Vinge has advised Industrifonden in connection with its MSEK 9 investment in the Malmö-based company, Anyfi Networks. The company’s existing stakeholders are also participating in the MSEK 10 new issue. The funds will be used for expansion and marketing purposes. Anyfi Networks provides technology which allows operators to offer a secure and automatic connection to an end-customer’s own home network irrespective of the actual location of the customer in question.

This is Industrifonden’s third investment for the financial year comprising 1 July 2012 to 30 June 2013. Industrifonden invests in small and medium-sized companies with international growth potential. The fund has assets of SEK 3.8 billion and has invested in 89 companies within the technology, cleantech, life science and industrial sectors.

Vinge’s team consisted of partner Johan Larsson together with associates Malin Buch and Evelina Tejle.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024